LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Corcept Therapeutics Inc

Închisă

SectorSănătate

73.21 -1.43

Rezumat

Modificarea prețului

24h

Curent

Minim

72.52

Maxim

75.47

Indicatori cheie

By Trading Economics

Venit

-9.8M

21M

Vânzări

-25M

157M

P/E

Medie Sector

64.591

50.291

EPS

0.169

Marjă de profit

13.069

Angajați

500

EBITDA

-22M

3.4M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+87.45% upside

Dividende

By Dow Jones

Următoarele câștiguri

28 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

165M

7.9B

Deschiderea anterioară

74.64

Închiderea anterioară

73.21

Sentimentul știrilor

By Acuity

49%

51%

157 / 380 Clasament în Healthcare

Corcept Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 iun. 2025, 20:51 UTC

Câștiguri

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 iun. 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 iun. 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 iun. 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 iun. 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 iun. 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:57 UTC

Achiziții, Fuziuni, Preluări

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 iun. 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 iun. 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 iun. 2025, 18:39 UTC

Market Talk
Câștiguri

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 iun. 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 iun. 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 iun. 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 iun. 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 iun. 2025, 17:08 UTC

Câștiguri

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 iun. 2025, 16:52 UTC

Achiziții, Fuziuni, Preluări

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 iun. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 iun. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 iun. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 iun. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 iun. 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 iun. 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparație

Modificare preț

Corcept Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

87.45% sus

Prognoză pe 12 luni

Medie 139.33 USD  87.45%

Maxim 145 USD

Minim 131 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCorcept Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

4

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

157 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.